Navigation Links
Leukemia inhibitory factor may be a promising target against pancreatic cancer
Date:6/19/2012

LAKE TAHOE, Nev. Pancreatic cancer is one of the deadliest forms of cancer, defying most treatments. Its ability to evade therapy may be attributable to the presence of cancer stem cells, a subset of cancer cells present in pancreatic tumors that drive tumor growth by generating bulk tumor cells. Cancer stem cells are notorious for their ability to resist traditional chemotherapies.

However, scientists at the University of California, San Francisco (UCSF), have discovered that two proteins KRAS and leukemia inhibitory factor (LIF) help create cancer stem cells and that the latter can be targeted to block them.

These results were presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here from June 18-21.

In many different types of tumors, a constitutively active, mutant form of the signaling protein KRAS helps drive the uncontrolled tumor cell proliferation that is a hallmark of cancer. In fact, more than 90 percent of pancreatic cancers exhibit KRAS mutations, but the link between KRAS and cancer stem cells has been tenuous until now.

Using human pancreatic cancer cell lines and mouse fibroblasts and pancreatic cancer cells, Man-Tzu Wang, Ph.D., a postdoctoral researcher in the McCormick lab at the Helen Diller Family Comprehensive Cancer Center at UCSF, and colleagues showed that KRAS causes cells to acquire and maintain stem cell-like properties.

"We know that KRAS is a very potent driver of pancreatic cancer, but we don't know how to drug it," said Wang. "Our results showed we can block KRAS-mediated cancer stem cells by blocking LIF activity."

KRAS is difficult to target therapeutically. Taking the next logical step, the researchers began looking for proteins that function downstream of KRAS in the generation of pancreatic cancer stem cells to determine if any of them could be potential drug targets. They found a number of candidates but focused on LIF, a protein known to regulate stem cell development. Moreover, they found that LIF is "druggable," making it a potential target for treatment.

Using neutralizing antibodies or shRNA, the team knocked down LIF activity or expression and found that each reduced the in vitro stem cell-like properties of mouse pancreatic cancer cells.

"We think our data indicate that blocking LIF can bring a significant improvement to cancer treatment," Wang said.

Knocking down cancer stem cells is critically important. Because these cells are slow-growing, they are often resistant to traditional chemotherapies, which target fast-growing cells. In addition, they also contain mechanisms that pump drugs out of the cell. Their survival allows them to continue to differentiate into mature cancer cells, leading to recurrent tumors.

Though there are no drugs currently available that target LIF, Wang is hopeful that these new data will spur the development of such products and generate new pancreatic cancer therapies.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Inhibitors of shuttle molecule show promise in acute leukemia
2. Marker distinguishes more-aggressive from less-aggressive forms of chronic leukemia
3. Child CT Scans Might Up Risk of Brain Cancer, Leukemia
4. Researchers identify a life-and-death molecule on chronic leukemia cells
5. New drug strategy attacks resistant leukemia and lymphoma
6. Inherited DNA change explains overactive leukemia gene
7. VCU Massey Cancer Center sees potential in novel leukemia treatment
8. A microRNA prognostic marker identified in acute leukemia
9. Study identifies potential treatment for lethal childhood leukemia
10. Therapy exploits addiction of leukemia cells
11. Study Shows New Option for Kids With Tough-to-Treat Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology: